Biovail Corporation announced that the US Federal Trade Commission (FTC) has concluded its inquiry regarding certain patent listings in the Food and Drug Administration's (FDA) Approved Drug Products with Therapeutic Equivalence Evaluations (also know as the FDA's Orange Book) for Teveten 600mg and Teveten HCT 600mg/12.5mg and 600mg/25mg, antihypertension medications currently sold by Biovail in the US The FTC has determined that it is satisfied that these patent listings are in accordance with the applicable rules and regulations and advised that the inquiry is now closed.

Biovail Corporation is an international full-service pharmaceutical company, engaged in the formulation, clinical testing, registration, manufacture, sale and promotion of pharmaceutical products utilizing advanced drug delivery technologies.